Clinical Trials · global
Can Correcting RNA Splicing Improve Muscle Function? PepGen Myotonic Dystrophy Trial Shows Early Signals
The six treated participants had an average 46.5% correction in muscle RNA splicing, alongside improvements in hand relaxation and grip strength. However, the small Phase 2 trial is not yet sufficient to establish efficacy, and patient-reported outcomes did not show consistent improvement.
For people with myotonic dystrophy type 1 (DM1), difficulty relaxing muscles after contraction can make everyday movements such as opening the hand challenging. Phase 2 trial results released by PepGen offer preliminary clues that addressing these difficulties at the RNA level may help: participants showed reduced RNA splicing abnormalities in their muscles, alongside signals of improvement in hand relaxation, grip strength, and mobility.
On November 10, PepGen released data from the 10 mg/kg dose group in the FREEDOM2-DM1 trial. This randomized, double-blind, placebo-controlled study enrolled eight participants in this group, with six receiving PGN-EDODM1 and two receiving placebo, administered intravenously every four weeks for a total of four doses. At Week 13, the treatment group had an average RNA splicing correction of 46.5%. BioCentury reported that five of the six participants exceeded 20% correction and four exceeded 50%, indicating individual differences behind the average.
DM1 is a progressive genetic disease in which abnormal repeat sequences in the DMPK gene disrupt RNA splicing, the process by which cells organize RNA in preparation for making proteins. PGN-EDODM1 is a peptide-conjugated oligonucleotide drug candidate being developed to address this molecular abnormality. However, the percentage of splicing correction represents a change in a biomarker and cannot be directly interpreted as the percentage of muscle strength restored or the extent of disease improvement.
Functional tests provided another layer of evidence. According to the company's results, at Week 16, the treatment group's video-measured hand-opening time was 3.9 seconds shorter than before treatment, an improvement of approximately 52.7%. Grip strength and tests of walking and getting up and moving also showed trends toward improvement. Both BioSpace and BioCentury viewed these changes as early signals: splicing correction in muscle may be accompanied by improvements in patients' actual function, but the relationship requires more thorough validation.
These results still have clear limitations. Only six participants received this dose, and some of the company's comparisons used pooled placebo data from two dose groups, totaling four participants. Differences in samples and baseline characteristics must be considered when interpreting the findings. Patient-reported outcomes were also inconsistent. In particular, the disease health index improved across all groups, including the placebo group, making it impossible to confirm whether changes on the tests have translated into improvements in daily life that patients consistently perceive.
On safety, the company said there were no serious adverse events or dose-limiting toxicities in this dose group, but four mild kidney-related adverse events were reported, and transient albuminuria was observed. No evidence of cumulative kidney toxicity was seen over 16 weeks, but this remains insufficient to address the risks of long-term repeated dosing. BioSpace also noted that a partial clinical hold at U.S. trial sites had not yet been lifted, while the study continued in other countries.
The next step will test whether these signals can be reproduced and sustained. PepGen said enrollment in the 12.5 mg/kg dose group was complete, with results expected in the first half of 2027. Whether a higher dose delivers additional benefits, whether splicing correction continues to correspond to functional improvements, and longer-term safety will all influence whether this therapy can advance toward more definitive clinical validation.